The open-label, phase II multicenter study is designed the influence the effect of subcutaneous injections of Aviscumine on progression-free survival and overall survival in patients with unresectable metastatic melanoma . Failure after treatment with cytostatics The study included 31 eligible patients and at four at four locations in Germany.

In stage III patients have developed regional metastasis, and 5-year survival rates between 25 percent and 60 percent, depending on the number of positive lymph nodes and metastases. Stage IV melanoma patients. 5 – year survival rates of between 9 percent and 15 percent only These either either distant skin, subcutaneous , or lymph node metastases or other visceral or distant metastases or elevated lactate dehydrogenase levels .. About metastatic melanomaWorldwide incidence of melanoma is about 160,000 cases per year treatments are surgical removal of the tumor, adjuvant therapy, chemotherapy and immunotherapy, or radiation therapy. If caught early, treatment often successfully removed the cancer. But in about 10 percent of the cases , patients develop metastatic melanoma, the stage III or stage IV is classified.However at 100 weeks, the patient that received OZ1 more circulating CD4+ cells of in their bloodstream: CD4+ cell are essential immune cell deliberately destroyed and by HIV.